



May 28, 2024

"Treated and untreated cows housed side by side in tie-stalls and their respective risk of harboring E. coli resistant to antimicrobials"

 [PLOS One](#)

DOI

<https://dx.doi.org/10.17504/protocols.io.j8nlk8ojxl5r/v1>

Belinda Köchle¹, Véronique ernier Gosselin¹, Heike Kaspar¹, Jens Becker¹

¹Clinic for Ruminants, Department of Clinical Veterinary Science, Vetsuisse-Faculty, University of Bern



Jens Becker

Clinic for Ruminants, Department of Clinical Veterinary Scie...

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

[Create free account](#)

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.j8nlk8ojxl5r/v1>

Protocol Citation: Belinda Köchle, Véronique ernier Gosselin, Heike Kaspar, Jens Becker 2024. "Treated and untreated cows housed side by side in tie-stalls and their respective risk of harboring E. coli resistant to antimicrobials". **protocols.io**

<https://dx.doi.org/10.17504/protocols.io.j8nlk8ojxl5r/v1>

License: This is an open access protocol distributed under the terms of the **[Creative Commons Attribution License](#)**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: May 28, 2024

Last Modified: May 28, 2024

Protocol Integer ID: 100701

Keywords: treated cow, untreated cow, resistant bacteria, carrying resistant bacteria, antimicrobial resistance, colonization of neighboring cow, neighboring cow, isolation of indicator escherichia, antimicrobial susceptibility, antimicrobial treatment, cows from other, cow, antimicrobial, bacteria, cows as source, farm management, associations of farm management, dairy farm, dairy, isolate

Funders Acknowledgements:

Fondation Sur-la-Croix (Basel, Switzerland)

Vontobel foundation (Zurich, Switzerland)

Abstract

Parenteral antimicrobial

treatment results in the excretion of antimicrobial-resistant bacteria. Dairy cows are commonly housed side by side in tie-stalls and often receive antimicrobial treatment. However, studies investigating treated cows as source of colonization of neighboring cows with resistant bacteria are scarce.

Antimicrobial resistance (AMR) in cows (treated and untreated) in tie-stalls was investigated to assess their respective risks of carrying resistant bacteria.

Furthermore, we analyzed associations of farm management with AMR. Case-control study: For isolation of indicator *Escherichia (E.) coli*, rectal swab

samples were taken. Cows were sampled depending on treatment history and proximity to one another (cow A: recently treated

parenterally; cow B: untreated, next to cow A; cow C: untreated, at considerable distance from all treated cows). Antimicrobial susceptibility was tested by microdilution. Associations of AMR with exposure to cow A, treatments, and management were analyzed using generalized mixed-effects logistic models. Susceptibility data on 571 isolates from 131 dairy farms were obtained. Almost no difference in proportions of resistant *E. coli* was observed between cows B and C (B: 53.4%; C: 57.2%; $P=0.52$). Untreated cows had lower odds of carrying resistant *E. coli* than treated cows (B: OR 0.44, $P<0.001$; C:

OR 0.54, $P=0.007$). Non-pansusceptibility of isolates was associated with antimicrobial treatment (1 treatment: OR 2.11, $P=0.001$; ≥ 2 : OR 1.76, $P=0.043$).

Using manure on forage crops was associated with higher odds of pansusceptibility (OR 2.01, $P=0.004$). For daily practice, with regard to the risk of AMR transmission, results of this study do not provide evidence for the need to separate treated cows from others during treatment in tie-stalls.

- 1
- 2 Materials and equipment:
- 3 Rectal swabs in transport tubes
- 4 BROLAC agar (Biolab, Budapest, Hungary)
- 5 MacConkey agar (Thermo Fisher Scientific, Basel, Switzerland)
- 6 Chromogenic coliform agar (Merck, Darmstadt, Germany)
- 7 Trypticase soy agar with 5% sheep blood (Becton Dickinson, Franklin Lakes, NJ, USA)
- 8 Columbia agar with 5% sheep blood (Becton Dickinson, Franklin Lakes, NJ, USA)
- 9 MALDI-TOF MS (Bruker, Bremen, Germany)
- 10 Microtubes with glycerol solution (Microbank™, Pro-Lab diagnostics, Wirral, UK)
- 11 Cation-adjusted Mueller-Hinton broth
- 12 EUVSEC3 Sensititre™ commercial test plates (Thermo Fisher Scientific, Basel, Switzerland)
- 13 Incubator set at 37 °C



- 14 Freezers at -20°C and -80°C
- 15 Personal protective equipment (lab coat, gloves etc.) Procedure:
- 16 Sample inoculation:
- 17 Within 24 hours of collection, remove rectal swabs from their transport tubes.
- 18 Directly spread the swabs onto the selected agar plates (BROLAC, MacConkey, or Chromogenic coliform agar). Note: ensure samples from the same triplet are inoculated onto the same type of agar.
- 19 Incubate the plates under aerobic conditions at 37 °C for 24 hours.
- 20 Colony selection and subculture:
- 21 After incubation, randomly select one single colony per plate.
- 22 Streak the selected colony onto trypticase soy agar containing 5% sheep blood or Columbia agar containing 5% sheep blood.
- 23 Incubate the plates at 37 °C for 24 hours.
- 24 Identification of *E. coli*:
- 25 Perform identification and confirmation of *E. coli* using MALDI-TOF MS.
- 26 Storage of isolates:
- 27 Suspend the confirmed *E. coli* isolates in microtubes with glycerol solution.

- 28 Store the microtubes at -20°C initially, and then transfer to -80°C for long-term storage.
- 29 Antimicrobial susceptibility testing (AST):
- 30 Thaw the frozen isolates and incubate on Columbia blood agar at 37 °C for 24 hours.
- 31 Determine the minimum inhibitory concentration (MIC) of antimicrobials using cation-adjusted Mueller-Hinton broth and EUVSEC3 Sensititre™ commercial test plates.
- 32 Classify the isolates as resistant (R) or susceptible (S) according to EUCAST clinical breakpoints. If not available, use CLSI recommendations.
- 33 Classification of isolates:
- 34 Classify isolates as 'pansusceptible' if susceptible to all tested drugs.
- 35 Classify as 'non-pansusceptible' if resistant to at least one tested drug.
- 36 Define isolates as 'multidrug-resistant' (MDR) if resistant to at least one drug from a minimum of three different antimicrobial classes. References:
- 37 EUCAST clinical breakpoints for Enterobacterales. Available from: https://www.eucast.org/clinical_breakpoints/ CLSI guidelines for antimicrobial susceptibility testing.]. Available from: <http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI+M100+ED32%3A2022&sbssok=CLSI+M100+ED32%3A2022+TABLE+2A&format=HTML#CLSI%20M100%20ED32:2022%20TABLE%20A>